Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease: The ADMIT Study: A Randomized Trial
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
CONTEXT: Although niacin increases low levels of high-density lipoprotein cholesterol (HDL-C), which frequently accompany diabetes, current guidelines do not recommend use of niacin in patients with diabetes because of concerns about adverse effects on glycemic control; however, this is based on limited clinical data. OBJECTIVE: To determine the efficacy and safety of lipid-modifying dosages of niacin in patients with diabetes. DESIGN AND SETTING: Prospective, randomized placebo-controlled clinical trial conducted in 6 clinical centers from August 1993 to December 1995. PARTICIPANTS: A total of 468 participants, including 125 with diabetes, who had diagnosed peripheral arterial disease. INTERVENTIONS: After an active run-in period, participants were randomly assigned to receive niacin (crystalline nicotinic acid), 3000 mg/d or maximum tolerated dosage (n = 64 with diabetes; n = 173 without diabetes), or placebo (n = 61 with diabetes; n = 170 without diabetes) for up to 60 weeks (12-week active run-in and 48-week double-blind). MAIN OUTCOME MEASURES: Plasma lipoprotein, glucose, hemoglobin A(1c) (HbA(1c)), alanine aminotransferase, and uric acid levels; hypoglycemic drug use; compliance; and adverse events, in patients with diabetes vs without who were receiving niacin vs placebo. RESULTS: Niacin use significantly increased HDL-C by 29% and 29% and decreased triglycerides by 23% and 28% and low-density lipoprotein cholesterol (LDL-C) by 8% and 9%, respectively, in participants with and without diabetes (P<.001 for niacin vs placebo for all). Corresponding changes in participants receiving placebo were increases of 0% and 2% in HDL-C and increases of 7% and 0% in triglycerides, and increases of 1% and 1% in LDL-C. Glucose levels were modestly increased by niacin (8.7 and 6.3 mg/dL [0.4 and 0.3 mmol/L]; P =.04 and P<.001) in participants with and without diabetes, respectively. Levels of HbA(1c) were unchanged from baseline to follow-up in participants with diabetes treated with niacin. In participants with diabetes treated with placebo, HbA(1c) decreased by 0.3% (P =.04 for difference). There were no significant differences in niacin discontinuation, niacin dosage, or hypoglycemic therapy in participants with diabetes assigned to niacin vs placebo. CONCLUSIONS: Our study suggests that lipid-modifying dosages of niacin can be safely used in patients with diabetes and that niacin therapy may be considered as an alternative to statin drugs or fibrates for patients with diabetes in whom these agents are not tolerated or fail to sufficiently correct hypertriglyceridemia or low HDL-C levels. JAMA. 2000;284:1263-1270
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Self-citationRubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 1×
“Similarly, in the Veterans Affairs HighDensity Lipoprotein Cholesterol Intervention Trial (VA-HIT), participants with diabetes experienced coronary heart disease event reduction with gemfibrozil equivalent to that observed in the entire cohort.(32) Although the effect of niacin on cardiovascular morbidity and mortalit…”
Self-citationBrown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Blankenhorn, D. H. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390230069027 · Cited by 1,655
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 845
Management of Dyslipidemia in Adults With Diabetes
Haffner, S. M. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.160 · Cited by 786
Influence of nicotinic acid on serum cholesterol in man
Altschul, R., Hoffer, A., & Stephen, J. D. (1955) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(55)90070-9 · Cited by 724
Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study
Koskinen, P., Mänttäri, M., Manninen, V., Huttunen, J. K., Heinonen, O. P., & Frick, M. H. (1992) · Diabetes Care · doi:10.2337/diacare.15.7.820 · Cited by 509
Predisposition to Atherosclerosis in the Head, Heart, and Legs: The Framingham Study
Gordon, T. (1972) · JAMA · doi:10.1001/jama.1972.03200200011003 · Cited by 340
Nicotinic Acid as Therapy for Dyslipidemia in Non—Insulin-Dependent Diabetes Mellitus
Garg, A. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450060069031 · Cited by 286
Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man
Grundy, S. M., Mok, H. Y., Zech, L., & Berman, M. (1981) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34737-4 · Cited by 270
Knopp, R. H., Ginsberg, J., Albers, J. J., Hoff, C., Ogilvie, J. T., Warnick, G. R., Burrows, E., Retzlaff, B., & Poole, M. (1985) · Metabolism · doi:10.1016/0026-0495(85)90092-7 · Cited by 231
Jin, F.-Y., Kamanna, V. S., & Kashyap, M. L. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.10.2020 · Cited by 193
Kahn, S. E., Beard, J. C., Schwartz, M. W., Ward, W. K., Ding, H. L., Bergman, R. N., Taborsky, G. J., & Porte, D. (1989) · Diabetes · doi:10.2337/diab.38.5.562 · Cited by 181
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial
Illingworth, D. R. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.14.1586 · Cited by 133
Gemfibrozil Alone and in Combination With Lovastatin for Treatment of Hypertriglyceridemia in NIDDM
Garg, A., & Grundy, S. M. (1989) · Diabetes · doi:10.2337/diab.38.3.364 · Cited by 85
Miettinen, T. A., Taskinen, M., Pelkonen, R., & Nikkilä, E. A. (1969) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1969.tb01473.x · Cited by 70
Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans
Gray, D. R., Morgan, T., Chretien, S. D., & Kashyap, M. L. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-4-199408150-00003 · Cited by 67
The effect of nicotinic acid in diabetes mellitus
Molnar, G. D., Berge, K. G., Rosevear, J. W., McGuckin, W. F., & Achor, R. W. P. (1964) · Metabolism · doi:10.1016/0026-0495(64)90131-3 · Cited by 64
Alvarsson, M., & Grill, V. (1996) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365519609088812 · Cited by 39
Dyslipidemias in Patients With Diabetes Mellitus: Classification and Risks and Benefits of Therapy
Oki, J. C. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb04369.x · Cited by 30
Rationale and design of the arterial disease multiple intervention trial (ADMIT) pilot study
Egan, D., Garg, R., Wilt, T. J., Pettinger, M. B., Davis, K. B., Crouse, J. R., Herd, J. A., Hunninghake, D. B., Sheps, D. S., Kostis, J. B., et al. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00915-1 · Cited by 21
Self-citation
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
“It can significantly increase blood glucose at high doses, but at modest doses (750–2,000 mg/day), significant improvements in LDL cholesterol, HDL cholesterol, and triglyceride levels are accompanied by only modest changes in glucose that are generally amenable to adjustment of diabetes therapy (370,379,380).”
BackgroundStandards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
“It can significantly increase blood glucose at high doses, but at modest doses (750–2,000 mg/day) significant improvements in LDL cholesterol, HDL cholesterol, and triglyceride levels are accompanied by only modest changes in glucose that are generally amenable to adjustment of diabetes therapy (299,309,310).”
BackgroundStandards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,724
Metadata
- Authors
- Elam, M. B., Hunninghake, D. B., Davis, K. B., Garg, R., Johnson, C., Egan, D., Kostis, J. B., Sheps, D. S., Brinton, E. A., & for the ADMIT Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2000-09-13
- Volume
- 284
- Issue
- 10
- Pages
- 1263
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2160689800
- Cited by
- 517
- References
- 26
- FWCI
- 26.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.